Missed Q4 2021 Earnings Takes a Blow on Calithera Biosciences Inc. (CALA) After Hours
Gule Rukhsar
April 1, 2022
The oncology-focused clinical-stage biopharmaceutical company, Calithera Biosciences Inc. (CALA) has been trodden down since its IPO. Falling by over 83.84% last year, 2022 has been